Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Titouan Cazaubiel

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Cancers|April 3, 2021
Multiple Myeloma: Heterogeneous in Every WayAnaïs Schavgoulidze, Titouan Cazaubiel, Aurore Perrot, et al.
Cancers|December 1, 2020
Risk and Response-Adapted Treatment in Multiple MyelomaTitouan Cazaubiel, Olga Mulas, Lydia Montes, et al.
Journal of Hematology|November 23, 2020
Reduce Mortality and Morbidity in Acute Myeloid Leukemia With Hyperleukocytosis With Early Admission in Intensive Care Unit: A Retrospective AnalysisNathan Mottal, Nahema Issa, Pierre-Yves Dumas, et al.
Ejhaem|January 29, 2025
Relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia responds well to a combination of modified hyper-CVAD, blinatumomab and tyrosine kinase inhibitorGaétan Basile, Jean Galtier, Titouan Cazaubiel, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 4, 2026
Real-World Evidence of Immunotherapy Sequencing in Multiple Myeloma: Durable Responses With BCMA-Targeting Bispecific Antibodies Following Prior GPRC5D-Targeting TherapyTitouan Cazaubiel, Cyrille Touzeau, Laure Vincent, et al.
British Journal of Haematology|May 7, 2022
VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapseLuc Heraudet, Jean Galtier, Simon Favre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2022
In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal PopulationsRomain Lannes, Mehmet Samur, Aurore Perrot, et al.
Clinical Hematology International|September 22, 2025
Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY StudyTitouan Cazaubiel, Olivier Decaux, Bruno Royer, et al.
Blood|April 21, 2024
RAS/RAF landscape in monoclonal plasma cell conditionsAnais Schavgoulidze, Jill Corre, Mehmet Kemal Samur, et al.
Blood|February 16, 2022
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical featuresTitouan Cazaubiel, Xavier Leleu, Aurore Perrot, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Cancers|April 3, 2021
Multiple Myeloma: Heterogeneous in Every WayAnaïs Schavgoulidze, Titouan Cazaubiel, Aurore Perrot, et al.
Cancers|December 1, 2020
Risk and Response-Adapted Treatment in Multiple MyelomaTitouan Cazaubiel, Olga Mulas, Lydia Montes, et al.
Journal of Hematology|November 23, 2020
Reduce Mortality and Morbidity in Acute Myeloid Leukemia With Hyperleukocytosis With Early Admission in Intensive Care Unit: A Retrospective AnalysisNathan Mottal, Nahema Issa, Pierre-Yves Dumas, et al.
Ejhaem|January 29, 2025
Relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia responds well to a combination of modified hyper-CVAD, blinatumomab and tyrosine kinase inhibitorGaétan Basile, Jean Galtier, Titouan Cazaubiel, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 4, 2026
Real-World Evidence of Immunotherapy Sequencing in Multiple Myeloma: Durable Responses With BCMA-Targeting Bispecific Antibodies Following Prior GPRC5D-Targeting TherapyTitouan Cazaubiel, Cyrille Touzeau, Laure Vincent, et al.
British Journal of Haematology|May 7, 2022
VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapseLuc Heraudet, Jean Galtier, Simon Favre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2022
In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal PopulationsRomain Lannes, Mehmet Samur, Aurore Perrot, et al.
Clinical Hematology International|September 22, 2025
Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY StudyTitouan Cazaubiel, Olivier Decaux, Bruno Royer, et al.
Blood|April 21, 2024
RAS/RAF landscape in monoclonal plasma cell conditionsAnais Schavgoulidze, Jill Corre, Mehmet Kemal Samur, et al.
Blood|February 16, 2022
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical featuresTitouan Cazaubiel, Xavier Leleu, Aurore Perrot, et al.
Pageof 2